Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29126767 | 0.87 | HPGD (0.53) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL11815554 | 0.87 | GAA (0.72) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL28532238 | 0.87 | NPSR1 (0.51) | GAANPSR1KDM4EMAPTTBXAS1 | |
| SCHEMBL7614830 | 0.87 | NPSR1 (0.51) | GAANPSR1KDM4EMAPTALDH1A1 | |
| SCHEMBL7854372 | 0.86 | GAA (0.51) | GAANPSR1MAPTALDH1A1HPGD | |
| SCHEMBL30350771 | 0.85 | GAA (0.55) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL12611682 | 0.85 | GAA (0.55) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL9267668 | 0.85 | GAA (0.70) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL1107148 | 0.85 | GAA (0.70) | GAANPSR1KDM4EHSD17B10MAPT | |
| SCHEMBL11550281 | 0.85 | GAA (0.70) | GAANPSR1KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483343-B | Novel sulfonyl chloride derivative, preparation method and application thereof | 泰州职业技术学院 | 2021-08-27 | — | — | CN | claimed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| CN-110483343-B | Novel sulfonyl chloride derivative, preparation method and application thereof | 泰州职业技术学院 | 2021-08-27 | — | — | CN | disclosed |
| CN-110483343-B | Novel sulfonyl chloride derivative, preparation method and application thereof | 泰州职业技术学院 | 2021-08-27 | — | — | CN | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-112469722-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
| WO-2020020097-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2020-01-30 | — | — | WO | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| EP-0758243-A4 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORP (US) | 1997-08-20 | — | — | EP | disclosed |
| EP-0758243-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWISa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| CN-1121718-A | Heterocyclic derivatives | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| EP-0696284-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1996-02-14 | — | — | EP | disclosed |
| WO-1995029682-A1 | BINDING OF E-SELECTIN, P-SELECTIN OR L-SELECTIN TO SIALYL-LEWISx OR SIALYL-LEWIS?a¿ | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-11-09 | — | — | WO | disclosed |
| US-5444050-A | Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| WO-1994025459-A1 | HETEROCYCLIC DERIVATIVES | ZENECA LIMITED (GB) | 1994-11-10 | — | — | WO | disclosed |
| US-4156011-A | TREATMENT OF CARDIOVASCULAR DISORDERS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | GAA 2360/4885NPSR1 4048/4885KDM4E 742/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | GAA 2360/4885NPSR1 4048/4885KDM4E 742/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | GAA 2392/4885NPSR1 712/4885KDM4E 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.